unclear whether they will engage the required components of the innate and adaptive immune responses to confer long-term protection. Following the report [3] that immunization with x-irradiated Plasmodium gallinaceum sporozoites (spz) confers protective immunity, the use of radiation-attenuated P. falciparum spz (Pf g-spz)-nonreplicating, live parasites-as an effective vaccine has been demonstrated in humans [4] .
At present, Pf g-spz are the only vaccine inducing lasting and sterile protection in malaria-naive subjects of diverse HLA backgrounds [5] . The use of radiation for spz attenuation is, however, not without risk, because it yields heterogeneously attenuated spz. This process is also radiation dose sensitive [6] , and underirradiated spz remain infectious, whereas overirradiated spz are not sufficiently immunogenic to prevent infection [6, 7] . These problems prompted a search for other forms of attenuation that would render the parasite a more reliable vaccine.
Recently, we described the development of 2 genetically attenuated P. berghei parasites, each with a targeted disruption of a single but different gene up-regulated in infective spz and thus designated UIS3 [8] and UIS4 [9] . Both genes are essential for the development of liver-stage parasites. Although the protein encoded by the UIS4 gene localizes to the parasitophorous vacuole (PV) membrane [9] , UIS3 interacts with liver-fatty acid-binding protein within hepatocytes [10] . Immunizations of C57BL/6 mice with either P. berghei UIS3 (Pbuis3 [Ϫ] ) or UIS4 (Pbuis4 [Ϫ] ) mutants conferred protection against wildtype (WT) homologous challenge [8, 9] .
A single-gene knockout parasite might not be suitable as a vaccine for humans, because it could give rise to breakthrough infections. To safeguard against this possibility, we developed a double-knockout parasite, Pbuis3(Ϫ)/4(Ϫ) parasite in which both genes, UIS3 and UIS4, were deleted (K.M., data not shown). The question remained, however, whether the doubleknockout parasite is sufficiently immunogenic to induce protection. The mechanism of induction and maintenance of protection by the genetically attenuated plasmodia is unexplored, although it likely stems from the inability of arrested early liverstage parasites to develop into mature liver-stage schizonts [8, 9] . We and others [11, 12] have shown that treatment with primaquine, a drug that disrupts liver-stage parasites and, hence, prevents the expression of protein antigens, results in the loss of g-spz-induced long-term protection in rodents and a shorter time to reinfection in humans [13] . It is believed, therefore, that proteins from the arrested liver-stage parasites provide the key antigens required for the induction of effector CD8 + T cells and, possibly, for the maintenance of protection by memory CD8 + T cells [14] . The evidence that CD8 + T cells are the sine qua non effectors against liver-stage infection comes from the observations that adoptively transferred g-spz-immune CD8 + T cells confer protection [15] and that g-spz do not protect mice deficient in CD8 + T cells, either as a result of in vivo depletion of these cells [16] or b 2 m [17] or MHC class I (K b D b ) disruption [14] . In the Pfg-spz model, both CD8 + cytotoxic T lymphocyte [18] and interferon (IFN)-g responses are critical for protection against liver-stage parasites, and most of the current focus has shifted toward cytokine-producing CD8 + T cells. We have demonstrated that Pbg-spz-induced long-lasting, protective immunity is major histocompatibility complex (MHC) class I dependent [17] and is accompanied by the presence of CD8 + effector memory (T EM ) and central memory (T CM ) cells in the liver [12] . Whereas CD8 + T EM cells produce IFN-g in response to infectious challenge, CD8
+ T CM cells undergo homeostatic proliferation (U.K., personal observations) and thereby form the reservoir of memory T cells [14] .
In the present study, we tested the protective efficacy of + T cells that were recalled even after rechallenge at 6 months. This and other studies [8, 9, 19] showing that genetically attenuated plasmodia spz are efficient at inducing and maintaining protective immunity support our efforts to develop genetically attenuated P. falciparum spz as a pre-erythrocytic-stage vaccine for human use. [8, 9] .
MATERIALS AND METHODS

Mice
For P. berghei WT or Pbuis3(Ϫ)/4(Ϫ) spz production, Anopheles stephensi mosquitoes were fed on gametocyte-infected mice. Then, spz were dissected [12] from the salivary glands of mosquitoes 16-21 days after the blood meal and were used either immediately or after attenuation with gamma radiation (15,000 rad; Cesium-137 source Mark 1 series or Cobalt-60 Model 109; JL Shepard).
Immunizations. Mice were primed (iv) with 75,000 of either Pbg-spz [12] or Pbuis3(Ϫ)/4(Ϫ) spz followed by 2 boost immunizations of 20,000 homologous spz 1 week apart and were challenged with 10,000 infectious spz 1 week later. In some experiments, mice were rechallenged 6 months after challenge. In addition, various regimens of immunization and challenge were performed with Pbuis3(Ϫ)/4(Ϫ) spz. These included 3 immunizations of 10,000 Pbuis3(Ϫ)/4(Ϫ) spz given 1 week apart followed by a challenge of 10,000 infectious spz on day 7 or 118 after the last immunization. Thin blood smears were prepared from individual mice starting on day 2 after challenge, and parasitemia was determined microscopically using Giemsa stain. Mice were considered protected if parasites were not detected in 40 fields by day 14 after challenge.
Cell preparation. At various time points after immunization, mice were euthanized by CO 2 inhalation. Livers were perfused with 10 mL of PBS, removed, and pressed through a 70-mm nylon cell strainer (BD Labware), and the cell suspension was processed as described elsewhere [12] . Briefly, cells were resuspended in PBS that contained 35% Percoll (Amersham Pharmacia Biotech) and centrifuged at 800 g for 20 min. Erythrocytes were lysed with lysis buffer (Sigma), and the remaining hepatic mononuclear cells (HMCs) were resuspended in complete RPMI 1640 medium. Spleens were removed aseptically, and single-cell suspensions were prepared as described above. For isolation of peripheral blood mononuclear cells (PBMCs), venous blood was collected into microtone tubes that contained K 2 EDTA (BD Biosciences). Erythrocytes were lysed, and the remaining PBMCs were washed in PBS and resuspended in complete RPMI 1640 medium.
Flow cytometry. Four-color staining of HMCs, spleen cells, or PBMCs was performed using a combination of the following monoclonal antibodies (MAbs): fluorescein isothiocyanate (FITC)-conjugated anti-CD45RB (16A), phycoerythrin (PE)-conjugated anti-CD44 (IM7), peridinin-chlorophyll-proteinconjugated anti-CD8a (Ly-2), and allophycocyanin (APC)-conjugated anti-CD44 (IM7) (BD Biosciences). Briefly, 2-10 ϫ 10 5 cells were resuspended in cold assay buffer (PBS containing 1% bovine serum albumin [BSA; Sigma] and 0.01% sodium azide) and incubated with anti-FcR 24G2 (BD Biosciences) and 0.5 mg of the relevant MAb for 30 min at 4ЊC. Cells were washed and resuspended in cold assay buffer. Flow cytometry was performed on a FACSCalibur (BD Biosciences), and data analysis was performed using CellQuest (version 3.3; BD Biosciences) or FlowJo software (version 8.1.0; Tree Star).
IFN-g secretion assay. IFN-g-producing CD8
+ T cells were detected as described elsewhere [12] using a secretion assay in accordance with the manufacturer's instructions (Miltenyi Biotec). Briefly, cells were resuspended in 90 mL cold assay 6 1 ϫ 10 buffer (PBS with 2 mmol/L EDTA and 0.5% BSA) that contained 10 mL of mouse IFN-g capture reagent and incubated on ice for 5 min. Cells were resuspended in 10 mL of RPMI and incubated for 45 min at 37ЊC in 5% CO 2 under continuous shaking. After washing, the cells were resuspended in 90 mL of cold buffer that contained 10 mL of PE-labeled IFN-g detection reagent, 1 mL of anti-CD3 FITC, and 1 mL of anti-CD8 APC and were incubated on ice for 10 min. After washing, the cells were resuspended in 500 mL of cold buffer. Then, 10 mL of 7-amino-actomycin D (25 mg/mL) was added to the cell suspension, and the sample was immediately analyzed by flow cytometry.
Antibody determinations. Serum from Pbuis3(Ϫ)/4(Ϫ) spz-immune WT and b 2 m
Ϫ/Ϫ mice was tested for circumsporozoite (CS) protein-specific antibodies by ELISA. Briefly, 2-fold serial dilutions of serum were dispensed into duplicate wells that had been previously coated with P. berghei glutathione S-transferase-CS protein (provided by Dr. E. Angov, WRAIR). The plates were incubated for 1 h at 22ЊC. After washes, 100 mL of anti-mouse IgG alkaline phosphatase conjugate (1 mg/ mL) was added and incubated for 1 h at 22ЊC. After washes, 100 mL of alkaline phosphatase substrate was added and incubated for 1 h at 22ЊC. The reaction was stopped with 10% SDS/H 2 O, and the plates were read on an ELISA plate reader (SPECTRAmax M2; Molecular Devices) using SoftmaxPro software (version 4.7.1; Molecular Devices) at 450 nm. Statistical analysis. Data are presented as the means ‫ע‬ SDs, and the differences among groups were analyzed by the Mann-Whitney U test using Graphpad Prism software (version 4.0c).
was considered to be statistically significant. P ! .05
RESULTS AND DISCUSSION
Sterile protection after immunization with Pbuis3(5)/4(5) spz. P. berghei parasites deficient in a single gene induce protection in mice [8, 9, 19] . However, single-knockout parasites may not be sufficiently attenuated and may compensate for loss of a single gene, resulting in an occasional breakthrough infections [9, 19] . To preclude this possibility, we constructed a novel double-knockout Pbuis3(Ϫ)/4(Ϫ) strain and tested its ability to confer sterile protection against homologous WT spz challenge in C57BL/6 mice. Mice were immunized with 75,000, 20,000, and 20,000 Pbg-spz or Pbuis3(Ϫ)/4(Ϫ) spz 1 week apart and challenged with 10,000 spz after the last immunization. In some cases, mice were rechallenged 6 months after the primary challenge. Whereas naive mice became parasitemic within 5-7 days after challenge, both Pbg-spz-and Pbuis3(Ϫ)/ 4(Ϫ) spz-immune mice were fully protected against primary and secondary (day 180) challenges (table 1) . A further investigation showed that 3 immunizations with 10,000 Pbuis3(Ϫ)/ 4Ϫ) spz also conferred full protection at challenge 118 days later (table 1) .
These data show for the first time that multiple immunizations with double-knockout Pbuis3(Ϫ)/4(Ϫ) spz confer sterile and long-lasting protection against P. berghei liver-stage infection. Collectively, 1100 mice remained solidly (100%) protected. Experiments are in progress to assess the duration of protective immunity beyond the initial 6-month period.
Hepatic CD8 + T EM cells induced by Pbuis3(5)/4(5) spz. Pbg-spz enter hepatocytes, where they undergo aborted development into liver-stage parasites that induce sterile immunity characterized by the presence of activated/memory hepatic CD8 + T cells. Because the knockout parasites also colonize hepatocytes [8, 9] , we sought to determine whether Pbuis3(Ϫ)/ 4(Ϫ) spz-induced protective immunity against P. berghei liverstage infection is also associated with the presence of activated/ memory hepatic CD8 + T cells. Hepatic and splenic CD8 + T cells isolated from Pbg-spz-and Pbuis3(Ϫ)/4(Ϫ) spz-immune mice were analyzed for the expression of the activation-related surface markers, CD44 and CD45RB, at different time points after priming and boost immunizations. Consistent with our previous observations with Pbg-spz [12] + T cells, and after the last boost immunization they increased to (figure 1), whereas CD8 + T CM cells 28% ‫ע‬ 5% concomitantly decreased from after priming to 25% ‫ע‬ 2% after boost immunization. The percentage of each 17% ‫ע‬ 2% CD8 + T cell subset at each time point examined was remarkably similar between the Pbg-spz-and Pbuis3(Ϫ)/4(Ϫ) spz-immune mice (figure 1). As previously reported for Pbg-spz [12, 20] , only a small percentage (! 10%) of CD8 + T EM cells was found in the spleens of Pbuis3(Ϫ)/4(Ϫ) spz-immune mice (data not shown), thus confirming the enrichment of CD8 + T EM cells in the liver, a nonlymphoid organ, which is the site of liver-stage malaria infection. n p 5 mice (n p 19) were immunized with 75,000, 20,000, and 20,000 Pbuis3(Ϫ)/4(Ϫ) sporozoites (spz) administered 1 week apart. One week after the final immunization, mice were challenged with 10,000 infectious P. berghei spz. Naive mice (n p 5) were used as infectivity controls. WT mice were rechallenged with 10,000 infectious P. berghei spz 6 months after the first challenge. Parasitemia was monitored by microscopy of Giemsa-stained blood smears every other day, starting 2 days after challenge. A, Percentage of mice remaining parasite free at the indicated time points. B, Average ‫ע‬ SE percentage of parasitized red blood cells per mouse. Immunized WT mice are indicated in by squares, immunized b 2 m Ϫ/Ϫ mice by triangles, and naive infectivity controls by diamonds.
Protracted protection induced by Pbuis3(5)/4(5) spz and associated with the persistence of hepatic CD8
+ T EM cells. We asked whether similar to Pbg-spz-induced immunity [12] , the Pbuis3(Ϫ)/4(Ϫ) spz-induced hepatic CD8 + T EM cells are maintained during protracted protection. In a longitudinal study, we measured the levels of CD8 + T EM and T CM cells at the indicated time points after the challenge and rechallenge ( figure  2A ). One week after challenge, the accumulation of CD8 + T EM cells peaked (∼60%) in both groups of mice, owing to either recruitment from the CD8 + T CM cells, to influx of extrahepatic cells into the liver, or to both. Numbers of hepatic CD8 + T EM cells in both groups decreased after the first week, presumably due to attrition, as observed during infection [21] . At 8 weeks after challenge, percentages of CD8 + T EM cells remained at ∼40% in both groups ( figure 2A) . To examine the recall of memory responses, mice were rechallenged at 6 months, and CD8 + T cells were analyzed for subset distribution. In the Pbgspz-protected mice, of hepatic CD8 + T cells were 25% ‫ע‬ 6% CD8 + T EM cells, whereas, in Pbuis3(Ϫ)/4(Ϫ) spz-protected mice, CD8
+ T EM cells represented of the total liver 42% ‫ע‬ 5% CD8 + T cells. The differences, however, were not statistically significant.
We also detected ∼20% of circulating CD8 + T EM cells in blood 6 days after spz challenge of both Pbuis3(Ϫ)/4(Ϫ) spz-and Pbg-spz-immune mice but not in the blood of naive mice ( figure 2B ). These observations demonstrate the feasibility of using peripheral blood CD8 + T cell subsets as a surrogate indicator of hepatic CD8 + T cells in human subjects participating in malaria vaccine trials, including those planned with the double-knockout P. falciparum spz. mice had a slight delay in the onset of parasitemia, and by day 5 only 50% of mice were parasitemic. In addition, although the level of parasitemia in both groups was 1% at day 5, it increased in the WT naive mice to 8% on day 7, whereas it remained at 2% in the b 2 m Ϫ/Ϫ mice ( figure 3B ).
Mediation by CD8 + T cells of protection against liver-stage infection in
Although the failure to achieve sterile protection in b 2 m Ϫ/Ϫ mice likely stems from the absence of surface expression of MHC class I molecules and, hence, CD8 + T cells, we wanted to rule out a possible defect in the antibody response as a contributor to this failure. It has been well established that Pbgspz-induced protection is multifactorial [22] and that CD4 T + helper cells [22] and B cells [23] play a significant role in mediating protective immunity. P. berghei CS protein-specific antibody titers of Pbuis3(Ϫ)/4(Ϫ) spz-immunized b 2 m Ϫ/Ϫ and WT mice were 24,150 and 27,875, respectively, and these differences were not statistically significant (figure 4). We presume that the delayed onset and lower level of parasitemia seen in Pbuis3(Ϫ)/4(Ϫ) spz-immunized b 2 m Ϫ/Ϫ mice were controlled in part by the CS protein-specific antibodies. This observation confirms previous findings from the Pbg-spz [24] and Py-spz [25] models that, although essential, antibody responses alone cannot mediate protection. Efficient IFN-g production by Pbuis3(5)/4(5) spz-immune CD8 + T cells. The exact mechanism by which CD8 + T cells confer protection is still not understood, although it is known that IFN-g can mediate the destruction of liver-stage infection [16, 26] . We [12] and others [27] ), and, after boost immunization, 4% ‫ע‬ 1% 1% ‫ע‬ 0.2% a 2.5-fold increase ( vs. ) was still evident. 5% ‫ע‬ 1% 2% ‫ע‬ 1% The peak response in both groups occurred at 24 h after challenge, although the percentage of IFN-g-producing CD8
+ T cells at this time was 1.6-fold higher in the Pbuis3(Ϫ)/4(Ϫ) spz-than in the Pbg-spz-immune-challenged mice (11% ‫ע‬ vs.
7% ‫ע‬ 2% lenged mice continued to exhibit a more robust response than the Pbg-spz-immune-challenged mice at 72 and 144 h after challenge with an ∼3-fold higher percentage of IFN-g-producing CD8 + T cells at both time points ( vs. 9% ‫ע‬ 0.5% and vs. at 72 and 144 h, 3% ‫ע‬ 0.6% 7% ‫ע‬ 0.2% 3% ‫ע‬ 0.5% respectively). The fluorescence data also revealed a higher intensity of IFN-g production by the Pbuis3(Ϫ)/4(Ϫ) spz-induced CD8 + T cells than in Pbg-spz-immune CD8 + T cells. Likewise, the attrition or contraction of the IFN-g-producing CD8
+ T cells was lower in Pbuis3(Ϫ)/4(Ϫ) spz-immune than in Pbg-spz-immune mice. To determine the recall of memory responses, mice in both groups were rechallenged at 6 months, and CD8 + T cells were analyzed for IFNg production. In Pbuis3(Ϫ)/4(Ϫ) spz-immune mice, of the hepatic 19% ‫ע‬ 2% CD8 + T cells produced IFN-g, whereas, in Pbg-spz-immune mice, IFN-g-producing CD8
+ T cells represented 14% ‫ע‬ 6% of liver CD8 + T cells. The differences, however, were not statistically significant. IFN-g-producing hepatic CD8 + T cells were not detected in the Pbuis3(Ϫ)/4(Ϫ) spz-immune-challenged b 2 m Ϫ/Ϫ mice (data not shown).
The data presented here show for the first time that genetically attenuated P. berghei spz with double gene deletions induced protective immunity that was long-lived and linked to MHC class I-dependent, IFN-g-producing hepatic memory CD8 + T cells. Although both Pbg-spz and Pbuis3(Ϫ)/4(Ϫ) spz promoted differentiation of CD8 + T cells into phenotypically similar T EM and T CM cell subsets, collectively, the data suggest that Pbuis3(Ϫ)/4(Ϫ) spz might be superior for the induction of protection. Although the mechanisms for this improved efficacy remain to be investigated, a number of scenarios could be considered. First, the Pbuis3(Ϫ)/4(Ϫ) spz might be more immunogenic than Pbg-spz, owing to differences in the state of the genes between the 2 parasite strains. Genetic attenuation disrupts specific genes, creating homogeneously arrested parasites, whereas attenuation by gamma radiation may damage genes randomly, leading to the loss of highly antigenic proteins. In addition, it is possible that genetic arrest is at a stage that best reflects the repertoire of protective antigens against subsequent transmission. By contrast, only a subpopulation of gspz might arrest at this point. Hence, relative to Pbg-spz, the Pbuis3(Ϫ)/4(Ϫ) spz could produce a broader spectrum of parasite antigens, some with high binding affinities to MHC class I molecules, which might be reflected in the robust IFN-g response.
The Pbuis3(Ϫ)/4(Ϫ) spz-derived proteins might engage antigen processing and presentation pathways more efficiently than proteins derived from Pbg-spz. It is relevant that the UIS4-encoded protein is associated with the PV membrane [9] that surrounds the parasite subsequent to its invasion of hepatocytes. Although Pyuis4(Ϫ) parasites form a PV membrane (S.H.I.K., data not shown), it is likely that the PV membrane has compromised function and may not protect the parasite from the host's intracellular proteolytic enzymes; instead, it might allow for a provision of a broader universe of antigenic proteins. Both the Pyuis3(Ϫ) and Pyuis4(Ϫ) parasites disappear by 40 h after invasion (S.H.I.K., data not shown), which might be partly explained by the leaky PV membranes surrounding the Pbuis3(Ϫ)/4(Ϫ) parasites. In turn, it is also possible that the leaky membranes might trigger early apoptosis of the invaded hepatocytes, thus leading to efficient cross-presentation by dendritic cells (DCs), of a wide spectrum of these liver-stage antigens [19] . Alternatively, some of these antigens may also be exported by the hepatocyte, possibly in the form of exosomes and subsequently taken up by DCs for presentation to CD8 + T cells [28] . It should be also noted that long-term retention of parasite antigens, possibly in the form of antigen-antibody complexes bound to follicular DCs could account for protracted recruitment of CD8 + T cells subsequent to the demise/ disappearance of the parasite.
Three doses of 10,000 Pbuis3(Ϫ)/4(Ϫ) can protect against an infectious spz challenge given 3 months after the last boost immunization without an intermittent infectious spz challenge. In conclusion, these are compelling data in support of the genetically attenuated plasmodia organisms as a pre-erythrocytic vaccine candidate and, thus, the development of genetically attenuated P. falciparum parasites for the use in phase Ia trials in humans is fully warranted.
